Evidence map›Paper›PMID 35214193›Full record

ArticlePharmaceutics2022

Hyaluronic Acid Nanoparticles for Immunogenic Chemotherapy of Leukemia and T-Cell Lymphoma.

Vinu Krishnan, Vimisha Dharamdasani, Shirin Bakre, Ved Dhole, Debra Wu, Bogdan Budnik, Samir Mitragotri

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Review
  3. Immunogenic Cell Death in Hematological Malignancy Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Vinu KrishnanSchool of Engineering and Applied Sciences, Harvard University, Cambridge, MA 02138, USA.ORCID 0000-0003-0098-7864
Vimisha DharamdasaniSchool of Engineering and Applied Sciences, Harvard University, Cambridge, MA 02138, USA.
Shirin BakreSchool of Engineering and Applied Sciences, Harvard University, Cambridge, MA 02138, USA.
Ved DholeSchool of Engineering and Applied Sciences, Harvard University, Cambridge, MA 02138, USA.
Debra WuSchool of Engineering and Applied Sciences, Harvard University, Cambridge, MA 02138, USA.
Bogdan BudnikMass Spectrometry Proteomics and Research Laboratory, FAS Division of Science, Harvard University, Cambridge, MA 02138, USA.ORCID 0000-0003-3622-2003
Samir MitragotriSchool of Engineering and Applied Sciences, Harvard University, Cambridge, MA 02138, USA.
Harvard University · US

Funding

Harvard University NA
6 · The paper itself

Abstract

Ratiometric delivery of combination chemotherapy can achieve therapeutic efficacy based on synergistic interactions between drugs. It is critical to design such combinations with drugs that complement each other and reduce cancer growth through multiple mechanisms. Using hyaluronic acid (HA) as a carrier, two chemotherapeutic agents-doxorubicin (DOX) and camptothecin (CPT)-were incorporated and tested for their synergistic potency against a broad panel of blood-cancer cell lines. The pair also demonstrated the ability to achieve immunogenic cell death by increasing the surface exposure levels of Calreticulin, thereby highlighting its ability to induce apoptosis via an alternate pathway. Global proteomic profiling of cancer cells treated with HA-DOX-CPT identified pathways that could potentially predict patient sensitivity to HA-DOX-CPT. This lays the foundation for further exploration of integrating drug delivery and proteomics in personalized immunogenic chemotherapy.

Indexed as

drug deliveryhyaluronic acid nanoparticlesleukemialymphoma

Identifiers

PMID35214193
PMCPMC8874923
OpenAlexW4212836308

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.